Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this...

Full description

Saved in:
Bibliographic Details
Published inClinical interventions in aging Vol. 8; pp. 457 - 464
Main Authors Tunn, Ulf W, Gruca, Damian, Bacher, Peter
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2013
Taylor & Francis Ltd
Dove Press
Dove Medical Press
Subjects
Androgen Deprivation Therapy
Antineoplastic Agents, Hormonal - chemistry
Antineoplastic Agents, Hormonal - pharmacology
Cancer
Care and treatment
Chemistry, Pharmaceutical
GnRH agonist
Gonadotropin releasing hormone
Humans
Leuprolide - chemistry
Leuprolide - pharmacology
leuprolide acetate
Leuprorelin acetate
Male
Oncology, Experimental
Physiological aspects
Prostate cancer
Prostatic Neoplasms - drug therapy
Review
androgen deprivation therapy
leuprolide acetate
prostate cancer
leuprorelin acetate
GnRH agonist
Online AccessGet full text

Cover

More Information
Summary:For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this therapy; however, their indicated treatment duration of 1 to 4 months was still not long enough to satisfy all medical needs. For this reason some manufacturers developed new injectable formulations that provide testosterone suppression for 6 months. This review article assesses key publications in order to compare these long-acting, commercially available, LA depot formulations and their clinical performance. The literature search identified 14 publications; by excluding reviews, duplications, and non-English articles, only three original papers describing clinical trial remained for review: two focused on microsphere-based LA formulations with either a 30 mg or 45 mg dose and one focused on a gel-based leuprorelin acetate with a 45 mg dose. All products were tested in individual clinical trials and have demonstrated their efficacy and safety.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-1998
1176-9092
1178-1998
DOI:10.2147/CIA.S27931